Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
Study Details
Study Description
Brief Summary
This clinical trial studies the effect of customized 3 dimensional (3D) printed oral tents on patients with head and neck cancer who are receiving radiotherapy. Oral stents are made from the impression of patients' mouth and cover patients' teeth and gums during radiation therapy. A customized, 3D-printed oral stent may help to reduce mouth blisters and/or sores that may develop in patients while receiving head and neck radiation therapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
PRIMARY OBJECTIVE:
- To evaluate the acute mucositis rates in non-target mucosa of patients who receive head and neck radiation with or without a customized 3D printed oral stent.
SECONDARY OBJECTIVES:
- To record patient reported outcomes during radiotherapy. II. To evaluate patient narcotic use during radiotherapy. III. To evaluate the imaging and dosimetric differences in head and neck radiotherapy with and without a customized 3D printed oral stent.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients wear 3D printed oral stent during standard of care radiotherapy.
ARM II: Patients receive standard of care during treatment.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Arm I (3D printed oral stent) Patients wear 3D printed oral stent during standard of care radiotherapy. |
Other: Best Practice
Receive standard of care
Other Names:
Other: Medical Device Usage and Evaluation
Wear 3D printed oral stent
|
| Active Comparator: Arm II (standard of care) Patients receive standard of care during treatment. |
Other: Best Practice
Receive standard of care
Other Names:
Other: Medical Device Usage and Evaluation
Wear 3D printed oral stent
|
Outcome Measures
Primary Outcome Measures
- Mucositis toxicity rates [Through study completion, an average of 1 year]
Rate of non-target mucose will be estimated along with the corresponding 95% confidence interval. Cochran-Mantel-Haenszel (CHM) test will be applied to compare mucositis rates between the two treatment arms. Logistic regression will be used to compare occurrence of mucositis between two arms, adjusting for the effects of stratification factors as well as other covariates. T test or Wilcoxon rank sum test will be used to compare three Olerud-Molander Ankle Score between two arms: a mean mucositis score, an extent of mucositis score, and a worst site score.
Secondary Outcome Measures
- Patient reported outcomes [Through study completion, an average of 1 year]
Will be assessed using the MD Anderson Symptom Inventory Head and Neck questionnaire. T test or Wilcoxon rank sum test will be used to compare scores of each item per time point or sums of scores across all items at each time point or sums across three time point per item between the two arms. Multivariate analyses such as linear regression model adjusting for the effects of covariates might be performed to compare patients reported outcomes. Appropriate data transformation will be performed if necessary for assumption of normality.
- Patients narcotics diaries [Through study completion, an average of 1 year]
Will record the worst, the least, the average pain score and pain score at present for each day. Will calculate the average of these 4 scores as a composite daily pain score.
- Imaging difference [Through study completion, an average of 1 year]
The set up error during radiation will be measured in each treatment arm.
- Dosimetric difference [Through study completion, an average of 1 year]
The radiation dose to healthy tissue will be measured in each treatment arm.
- Composite pain scores [Through study completion, an average of 1 year]
An area under curve of pain scores over two weeks (AUC2wks) will be calculated for each patient, and the t test or Wilcoxon rank sum test will be used to compare the AUC2wks of pain scores between the two arms, and between patients with and without occurrence of mucositis in their non-target mucosa. Will also fit linear mixed models including patients as random effects to compare the composite pain scores over two weeks between treatment arms. The linear mixed models will also be fitted to evaluate the association of composite pain scores with occurrence of their non-target mucosa.
- Number of narcotic pills used [Through study completion, an average of 1 year]
An AUC2wks will be calculated for each patient, and the t test or Wilcoxon rank sum test will be used to compare the AUC2wks of pain scores between the two arms, and between patients with and without occurrence of mucositis in their non-target mucosa. Will also fit linear mixed models including patients as random effects to compare the composite pain scores over two weeks between treatment arms.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient is dispositioned to receive definitive or adjuvant radiotherapy for treatment of a diagnosed head and neck malignancy that includes
-
Well lateralized tonsil cancer with no soft palate involvement and qualifies for ipsilateral radiotherapy
-
Well lateralized buccal cancer that qualifies for ipsilateral radiotherapy
-
Well lateralized parotid cancer that qualifies for ipsilateral radiotherapy
-
A cancer that involves the nasal cavity and does not require coverage of the oral cavity or oropharynx
-
A cancer that involves the maxillary sinus and does not require coverage of the oral cavity or oropharynx
-
A cancer that involves the base of tongue
-
Age 18 or older
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
-
The patient will receive radiotherapy with either cisplatin, carboplatin, or cetuximab
-
Signed study-specific consent form
Exclusion Criteria:
-
Prior head and neck radiotherapy
-
Patient is unable to fit a tongue-lateralizing or tongue-depressing stent
-
Severe trismus with an incisal opening of < 10 mm
-
Inability to comply with the study procedures
-
Patients younger than 18 years of age
-
Patients must not be pregnant
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Banner Health/Banner Research | Phoenix | Arizona | United States | 85006 |
| 2 | Baptist MD Anderson Cancer Center | Jacksonville | Florida | United States | 32207 |
| 3 | Cooper Hospital University Medical Center | Camden | New Jersey | United States | 08103 |
| 4 | M D Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- M.D. Anderson Cancer Center
Investigators
- Principal Investigator: Eugene J Koay, M.D. Anderson Cancer Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 2020-1153
- NCI-2021-03221
- 2020-1153